Shares of biopharmaceutical company Liquidia Corporation (LQDA) were rising more than 12 percent in pre-market on Monday to $14.45, after the U.S. district court denied United Therapeutics' request to block the launch of Liquidia's Yutrepia inhalation powder to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).
"The ruling reinforces the clear path for the U.S. Food and Drug Administration to issue a final decision on the amended New Drug Application for Yutrepia," Liquidia said in a statement.
Liquidia shares had closed at $12.87, up 0.08 percent on Friday. The stock has been trading in the range of $5.71 - $16.99 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.